vs
Adaptive Biotechnologies Corp（ADPT）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
Adaptive Biotechnologies Corp的季度营收约是RECURSION PHARMACEUTICALS, INC.的2.0倍（$71.7M vs $35.5M），Adaptive Biotechnologies Corp净利率更高（-18.9% vs -304.2%，领先285.3%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 51.0%），Adaptive Biotechnologies Corp自由现金流更多（$1.4M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 30.8%）
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
ADPT vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $71.7M | $35.5M |
| 净利润 | $-13.6M | $-108.1M |
| 毛利率 | 74.6% | 59.8% |
| 营业利润率 | -17.8% | -304.8% |
| 净利率 | -18.9% | -304.2% |
| 营收同比 | 51.0% | 681.7% |
| 净利润同比 | 59.7% | 39.6% |
| 每股收益（稀释后） | $-0.08 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $71.7M | $35.5M | ||
| Q3 25 | $94.0M | $5.2M | ||
| Q2 25 | $58.9M | $19.2M | ||
| Q1 25 | $52.4M | $14.7M | ||
| Q4 24 | $47.5M | $4.5M | ||
| Q3 24 | $46.4M | $26.1M | ||
| Q2 24 | $43.2M | $14.4M | ||
| Q1 24 | $41.9M | $13.8M |
| Q4 25 | $-13.6M | $-108.1M | ||
| Q3 25 | $9.5M | $-162.3M | ||
| Q2 25 | $-25.6M | $-171.9M | ||
| Q1 25 | $-29.9M | $-202.5M | ||
| Q4 24 | $-33.7M | $-178.9M | ||
| Q3 24 | $-32.1M | $-95.8M | ||
| Q2 24 | $-46.2M | $-97.5M | ||
| Q1 24 | $-47.5M | $-91.4M |
| Q4 25 | 74.6% | 59.8% | ||
| Q3 25 | 80.7% | -183.8% | ||
| Q2 25 | 69.4% | -4.9% | ||
| Q1 25 | 67.6% | -48.0% | ||
| Q4 24 | 62.0% | -181.4% | ||
| Q3 24 | 64.1% | 53.7% | ||
| Q2 24 | 55.3% | 36.2% | ||
| Q1 24 | 56.9% | 19.1% |
| Q4 25 | -17.8% | -304.8% | ||
| Q3 25 | 10.9% | -3327.6% | ||
| Q2 25 | -42.5% | -916.8% | ||
| Q1 25 | -56.4% | -1297.9% | ||
| Q4 24 | -71.3% | -4042.4% | ||
| Q3 24 | -70.3% | -377.1% | ||
| Q2 24 | -109.6% | -697.4% | ||
| Q1 24 | -116.5% | -698.4% |
| Q4 25 | -18.9% | -304.2% | ||
| Q3 25 | 10.2% | -3135.3% | ||
| Q2 25 | -43.5% | -894.2% | ||
| Q1 25 | -56.9% | -1373.3% | ||
| Q4 24 | -71.0% | -3935.5% | ||
| Q3 24 | -69.1% | -367.5% | ||
| Q2 24 | -107.0% | -676.6% | ||
| Q1 24 | -113.5% | -662.4% |
| Q4 25 | $-0.08 | $-0.17 | ||
| Q3 25 | $0.06 | $-0.36 | ||
| Q2 25 | $-0.17 | $-0.41 | ||
| Q1 25 | $-0.20 | $-0.50 | ||
| Q4 24 | $-0.22 | $-0.56 | ||
| Q3 24 | $-0.22 | $-0.34 | ||
| Q2 24 | $-0.31 | $-0.40 | ||
| Q1 24 | $-0.33 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $70.5M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $218.8M | $1.1B |
| 总资产 | $512.7M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $70.5M | $743.3M | ||
| Q3 25 | $55.0M | $659.8M | ||
| Q2 25 | $43.2M | $525.1M | ||
| Q1 25 | $50.6M | $500.5M | ||
| Q4 24 | $47.9M | $594.4M | ||
| Q3 24 | $38.1M | $427.6M | ||
| Q2 24 | $59.8M | $474.3M | ||
| Q1 24 | $71.2M | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $218.8M | $1.1B | ||
| Q3 25 | $204.4M | $1.0B | ||
| Q2 25 | $179.7M | $919.1M | ||
| Q1 25 | $190.4M | $933.9M | ||
| Q4 24 | $202.7M | $1.0B | ||
| Q3 24 | $223.8M | $524.6M | ||
| Q2 24 | $241.6M | $584.4M | ||
| Q1 24 | $274.9M | $401.2M |
| Q4 25 | $512.7M | $1.5B | ||
| Q3 25 | $490.6M | $1.4B | ||
| Q2 25 | $496.6M | $1.3B | ||
| Q1 25 | $510.9M | $1.3B | ||
| Q4 24 | $539.4M | $1.4B | ||
| Q3 24 | $558.5M | $726.5M | ||
| Q2 24 | $584.9M | $775.9M | ||
| Q1 24 | $620.3M | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.1M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $1.4M | $-47.3M |
| 自由现金流率自由现金流/营收 | 2.0% | -133.1% |
| 资本支出强度资本支出/营收 | 0.9% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-48.9M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $2.1M | $-46.1M | ||
| Q3 25 | $-7.1M | $-117.4M | ||
| Q2 25 | $-12.4M | $-76.4M | ||
| Q1 25 | $-28.5M | $-132.0M | ||
| Q4 24 | $-12.5M | $-115.4M | ||
| Q3 24 | $-27.1M | $-59.2M | ||
| Q2 24 | $-17.3M | $-82.2M | ||
| Q1 24 | $-38.4M | $-102.3M |
| Q4 25 | $1.4M | $-47.3M | ||
| Q3 25 | $-7.5M | $-117.6M | ||
| Q2 25 | $-13.1M | $-79.6M | ||
| Q1 25 | $-29.7M | $-133.8M | ||
| Q4 24 | $-12.6M | $-116.7M | ||
| Q3 24 | $-27.4M | $-63.8M | ||
| Q2 24 | $-19.0M | $-83.4M | ||
| Q1 24 | $-39.9M | $-109.0M |
| Q4 25 | 2.0% | -133.1% | ||
| Q3 25 | -8.0% | -2272.5% | ||
| Q2 25 | -22.2% | -413.9% | ||
| Q1 25 | -56.7% | -907.4% | ||
| Q4 24 | -26.5% | -2567.7% | ||
| Q3 24 | -59.0% | -244.6% | ||
| Q2 24 | -44.1% | -578.5% | ||
| Q1 24 | -95.2% | -789.9% |
| Q4 25 | 0.9% | 3.5% | ||
| Q3 25 | 0.4% | 4.7% | ||
| Q2 25 | 1.1% | 16.4% | ||
| Q1 25 | 2.4% | 12.4% | ||
| Q4 24 | 0.2% | 28.6% | ||
| Q3 24 | 0.7% | 17.5% | ||
| Q2 24 | 4.0% | 8.2% | ||
| Q1 24 | 3.6% | 48.2% |
| Q4 25 | — | — | ||
| Q3 25 | -0.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
RXRX
暂无分部数据
